See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Cullinan’s cytokine therapy CLN-617 cleared to enter clinic for solid tumors

March 28, 2023
Cullinan Oncology Inc. has received IND clearance from the FDA to conduct a phase I trial of CLN-617 in patients with advanced solid tumors.
BioWorld Science Cancer Immuno-oncology FDA IND